Factors associated with neutralizing antibody levels induced by two inactivated COVID-19 vaccines for 12 months after primary series vaccinationArticle Published on 2022-09-092022-11-15 Journal: Frontiers in Immunology [Category] SARS, 진단, [키워드] age analyzed anti-SARS-CoV-2 antibody BBIBP-CorV blood sample booster dose booster doses change Chi-square China convalescent convalescent sera CoronaVac COVID-19 COVID-19 vaccine cross-sectional Cytopathic effect dose enrolled evaluated Factor Factors FIVE geometric mean concentration geometric mean titer GMC GMT immune immune persistence immunogenicity Immunoglobulin inactivated individual Influencing factors linear models Logistic regression NAb neutralizing antibody NIBSC nine number ranged real-world data recipient recipients sample sizes SARS-CoV-2 SARS-CoV-2 strain seropositive Seropositivity Sex Standard subject understanding vaccination Vaccine Vaccines Vero Cell were measured WHO Zhejiang [DOI] 10.3389/fimmu.2022.967051 PMC 바로가기
A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies혈액암이 있는 성인 환자의 SARS-CoV-2 백신 1차 및 2차 접종에 대한 면역 반응의 체계적인 검토 및 메타 분석Review Published on 2022-09-012022-09-11 Journal: International immunopharmacology [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] 95% confidence interval 95%CI affected affecting anti-CD20 therapy antibody Antibody detection Antibody Response article booster dose booster doses calculated Cancer patients chronic lymphocytic leukemia CLL Complete conducted coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines develop Diagnosis disease doses evaluate first dose Google Google Scholar healthy subject healthy subjects Hematological malignancies Hematological malignancy higher risk highlight highlighting immune response Immunity immunization Immunocompromised immunogenicity immunosuppressive IMPROVE kinase inhibitors less leukemia lowest Lymphocytic leukemia lymphoma malignancy measure Meta-analysis mRNA mRNA-1273 Myeloma Patient Primary outcome response rate SARS-CoV-2 SARS-CoV-2 vaccine second dose secondary outcome Secondary outcomes seropositive Seropositivity severe coronavirus disease solid tumor solid tumors status subgroup subtype systematic review the disease the vaccine tumors tyrosine tyrosine kinase inhibitor tyrosine kinase inhibitors Vaccine vaccine dose vaccine's immunogenicity Web of Science [DOI] 10.1016/j.intimp.2022.109046 PMC 바로가기 [Article Type] Review
Persistence and Protective Potential of SARS-CoV-2 Antibody Levels After COVID-19 Vaccination in a West Virginia Nursing Home CohortArticle Published on 2022-09-012022-11-15 Journal: JAMA Network Open [Category] SARS, 변종, 진단, [키워드] 95% CI absorbance Ad26.COV2.S age Analysis Anti-RBD IgG antibody antibody level Antibody Response association binding domain blood sample BNT162b2 booster booster doses Breakthrough infection calculated calibrator COVID-19 COVID-19 vaccination COVID-19 vaccine cross-sectional Delta demonstrated effective home Humoral immunity IgG IgG level increased risk individual Infection Level median multivariate no difference Nursing omicron outcome participant persistence populations Potential protective role regression modeling RNA-1273 SARS-CoV-2 SARS-CoV-2 antibody SARS-COV-2 infection SARS-CoV-2 surveillance SARS-CoV-2 vaccination SARS-CoV-2 vaccine SARS-CoV-2 variant Sex significantly higher significantly lower specimen subsequent the mean vaccination Vaccine Virginia were assessed West white [DOI] 10.1001/jamanetworkopen.2022.31334 PMC 바로가기
Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2SARS-CoV-2 Omicron 하위 계통 BA.1, BA.1.1 및 BA.2의 중화Article Published on 2022-08-102022-09-11 Journal: Cell Host & Microbe [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] BA.1 BA.1.1 BA.2 booster doses Booster vaccine COVID-19 COVID-19 patient dose highlight Immune escape Immunity individuals lineages mRNA mRNA vaccine natural infection neutralization neutralized Neutralizing antibodies neutralizing antibody omicron overcome patient sera patients recent Recovered COVID-19 patients SARS-CoV-2 sensitivity sera Vaccine variant while [DOI] 10.1016/j.chom.2022.04.014 PMC 바로가기 [Article Type] Article
Effectiveness of mRNA COVID-19 vaccines against Omicron and Delta variants in a matched test-negative case-control study among US veterans미국 참전용사를 대상으로 실시한 대조 테스트 음성 사례 대조 연구에서 오미크론 및 델타 변이체에 대한 mRNA COVID-19 백신의 효과Article Published on 2022-08-032022-09-11 Journal: BMJ Open [Category] SARS, 변종, [키워드] 95% CI Against Antigen booster booster dose booster doses booster vaccination case-control study Comorbidities conducted death Delta delta variant dose effective Effectiveness Electronic health record Epidemiology Health health administration health record hospitalisation immunology Infection male Messenger RNA mRNA mRNA COVID-19 vaccine mRNA vaccine mRNA vaccines Older omicron outcome positive result public health SARS-CoV-2 PCR SARS-CoV-2 test SARS-CoV-2 variant severe disease Symptoms the vaccine vaccination vaccinee vaccinees variant variants veteran [DOI] 10.1136/bmjopen-2022-063935 PMC 바로가기 [Article Type] Article
Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trialsAd26.COV2.S의 1회 투여에 의해 유도된 지속적인 항체 반응 및 부스팅 후 상당한 증가: 2건의 무작위 임상 시험Article Published on 2022-07-302022-09-11 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] Ad26 Ad26.COV2.S age analyzed anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody antibody Antibody Response Beta Beta variant binding binding antibodies binding antibody boost booster booster dose booster doses Cohort COV2.S COVID-19 determined by dose double-blind effective elicited enrolled enzyme enzyme-linked immunosorbent enzyme-linked immunosorbent assay evaluated followed by groups Identifier immune memory immunization immunosorbent increase in initial magnitude Neutralization assay Neutralizing antibodies neutralizing antibody Neutralizing antibody response neutralizing antibody responses participant Phase 2 Placebo placebo-controlled pseudotyped Randomized randomized clinical trial response robust Single-dose trials vaccination Vaccine vaccine dose variant Viral viral particle Virus neutralization virus neutralization assay [DOI] 10.1016/j.vaccine.2022.05.047 PMC 바로가기 [Article Type] Article
Antibody response following the third and fourth SARS-CoV-2 vaccine dose in individuals with common variable immunodeficiencyObservational Study Published on 2022-07-282022-10-05 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 임상, [키워드] Affect antibody Antibody Response booster booster doses Capsule clinical Concentration corona vaccination COVID-19 CVID dose examined IgG antibody immunodeficiency immunoglobulin replacement therapy IMPROVE increase in individual Kruskal-Wallis tests median monoclonal antibody mounted mRNA Multiple non-responder non-responders Patient patients proportion SARS-CoV-2 vaccination SARS-CoV-2 vaccine SARS-CoV-2 vaccines SARS-CoV2 Seroconversion seroconverted spike receptor-binding domain stimulate the antibody response Treatment vaccination Vaccinations Vaccine vaccine dose [DOI] 10.3389/fimmu.2022.934476 PMC 바로가기 [Article Type] Observational Study
Contribution of Two-Dose Vaccination Toward the Reduction of COVID-19 Cases, ICU Hospitalizations and Deaths in Chile Assessed Through Explanatory Generalized Additive Models for Location, Scale, and Shape위치, 규모 및 모양에 대한 설명 일반화 가법 모델을 통해 평가된 칠레의 COVID-19 사례, ICU 입원 및 사망 감소를 위한 2회 접종 백신의 기여Article Published on 2022-07-272022-09-11 Journal: Frontiers in Public Health [Category] COVID19(2023년), SARS, 변종, [키워드] Additive adverse outcome adverse outcomes booster dose booster doses contribute country COVID-19 death deaths dose epidemiological epidemiological data explain explanatory models Future future work GAMLSS models Generalized highlight Hospitalization ICU ICU hospitalizations Inclusion initial location mass vaccination Model outcome pandemic pandemic progresses per day Policy predictor provide R 2 reduce reducing SARS-COV-2 infection scale second dose shape statistical interaction statistically significant Stress Support vaccination vaccination schedule Vaccination Status vaccine doses Vaccines variant were used [DOI] 10.3389/fpubh.2022.815036 PMC 바로가기 [Article Type] Article
Solanaceae Family Phytochemicals as Inhibitors of 3C-Like Protease of SARS-CoV-2: An In Silico AnalysisSARS-CoV-2의 3C 유사 프로테아제 억제제로서의 가지과 식물 화학물질: 실리코 분석Article Published on 2022-07-252022-09-11 Journal: Molecules [Category] COVID19(2023년), SARS, 치료제, [키워드] anthocyanidins anthocyanin anthocyanins Antiviral binding energy booster doses caused China Compound coronavirus SARS-CoV-2 country COVID-19 death derivative dose drug drugs Effectiveness eggplant examined family global pandemic in silico incanumine. Infection MPro phytochemical predicted protease Research resulting Russia SARS-CoV-2 SARS-CoV-2 replication silico studies Solanaceae the vaccine USA vaccinate Vaccine Vaccines virus Wuhan Wuhan, China [DOI] 10.3390/molecules27154739 PMC 바로가기 [Article Type] Article
Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated – VISION Network, 10 States, December 2021-June 2022SARS-CoV-2 Omicron BA.1 및 BA.2/BA.2.12.1 하위 계통이 우세한 기간 동안 면역적격 성인 중 2, 3 및 4 COVID-19 mRNA 백신 용량의 효과 - VISION Network, 10개 주, 2021년 12월 -2022년 6월Article Published on 2022-07-222022-09-11 Journal: Morbidity and Mortality Weekly Report [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI accounted B.1.1.529 BNT162b2 booster dose booster doses Care cause conditions COVID-19 COVID-19 case COVID-19 vaccine Diagnosis dose Effectiveness eligible estimate evade evaluate examined Hospitalization initial median moderate moderate to severe mRNA mRNA COVID-19 vaccine mRNA COVID-19 vaccines mRNA-1273 network omicron Omicron variant pattern Period Pfizer-BioNTech Prevent real-world data receipt receive reduced SARS-CoV-2 SARS-COV-2 infection severe COVID-19 the United State United States vaccination Vaccine-induced immunity variant virus [DOI] 10.15585/mmwr.mm7129e1 PMC 바로가기 [Article Type] Article